ProCE Banner Activity

CHRYSALIS Phase I Trial: Amivantamab + Lazertinib in Osimertinib-Relapsed, Chemotherapy-Naive EGFR-Mutated Advanced NSCLC, Including Analyses of Biomarkers of Response

Slideset Download
Conference Coverage
Amivantamab plus lazertinib achieved an ORR of 36% in chemotherapy-naive patients with disease progression on first-line osimertinib.

Released: June 09, 2021

Expiration: June 08, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme